Search

Displaying results 2651 - 2660 of 10000 in total
  1. Drug

    Almonertinib

    go.drugbank.com/drugs/DB16640
    ApprovedInvestigational

    [A231859, A231864, A231869] Unlike other third-generation EGFR TKIs, almonertinib is a pyrimidine-based drug that forms a covalent bond to the binding site of the EGFR tyrosine kinase domain. … [A231859] On March 19, 2020, almonertinib was approved in China for the treatment of EGFR T790M+ non-small cell lung cancer.[A231864] Almonertinib was also approved by the EMA on February 20, 2026.

    Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
  2. Drug

    Rilonacept

    go.drugbank.com/drugs/DB06372
    ApprovedInvestigational

    Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. … Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS)

    Categories: Interleukin-1 Receptor Accessory Protein
  3. Drug

    Omega-3-acid ethyl esters

    go.drugbank.com/drugs/DB09539
    ApprovedInvestigational

    Omega-3-acid ethyl esters are currently marketed in the US, EU, and many other regions under the brand name Lovaza[FDA Label][L5849]. … Omega-3-acid ethyl esters are prescription drugs that contain eicosapentaenoic acid-ethyl ester (EPA) and docosahexaenoic acid-ethyl ester (DHA) that are used in combination with changes in diet to lower

    Mixtures: ROSUVASTATINA E OMEGA 3 SPA SOCIET PRODOTTI ANTIBIOTICI, ROSUVASTATINA E OMEGA 3 SPA SOCIET PRODOTTI ANTIBIOTICI
  4. Drug

    Lotilaner

    go.drugbank.com/drugs/DB17992
    ApprovedInvestigationalVet approved

    The active ingredient found in drug products of lotilaner is the S-enantiomer. … [A260746, L47556] Lotilaner consists of two enantiomers: the S-enantiomer is active _in vivo_, while the R-enantiomer is reported to exhibit low biological activity.

  5. Drug

    Cefmenoxime

    go.drugbank.com/drugs/DB00267
    Approved

    It is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria. … Cefmenoxime is a novel broad-spectrum and third-generation cephalosporin antibiotic that is typically used in the treatment of female gynecologic and obstetric infections.

    Synonyms: (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  6. Drug

    Cetuximab

    go.drugbank.com/drugs/DB00002
    ApprovedInvestigational

    Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor … [A227973] EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelial tissue development and homeostasis.

    Categories: Epidermal Growth Factor Receptor Antagonist, EGFR (Epidermal Growth Factor Receptor) inhibitors
  7. Drug

    Loratadine

    go.drugbank.com/drugs/DB00455
    ApprovedInvestigational

    Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis.

    Mixtures: DE-COLD S.R.F.C TABLETS
  8. Drug

    Fluorodopa (18F)

    go.drugbank.com/drugs/DB13848
    ApprovedInvestigational

    [L12849] Fluorodopa F 18 PET is used adjunctly with other diagnostic investigations and serves primarily to visualize dopaminergic nerve terminals in the striatum.[L12849] … Fluorodopa F 18 is a fluorinated analog of [levodopa] used as a diagnostic agent for positron emission tomography (PET) in the evaluation of Parkinsonian syndromes.

  9. Drug

    Telisotuzumab vedotin

    go.drugbank.com/drugs/DB15104
    ApprovedInvestigational

    to be approved for this specific patient population. … [L53158] The c-Met protein is found to be overexpressed in approximately 25% of advanced EGFR wild type, non-squamous NSCLC patients and is associated with poor prognosis and limited treatment options.

  10. Drug

    Didanosine

    go.drugbank.com/drugs/DB00900
    ApprovedInvestigational

    A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. … This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains.

    Products: BRISTOL VIDEX TABLETAS DE 150 MG, DE LIBERACION RETARDADA X 125 MG